HealthDay News) — Reduced overall survival (OS) is seen for patients with alcohol-related hepatocellular carcinoma (HCC), according to a study published online March 28 in Cancer.

Charlotte E. Costentin, MD, from the Public Hospital System of Paris, and colleagues compared HCC characteristics and outcomes among an alcohol-related group (group A; 582 patients) and a nonalcohol-related group (group NA; 312 patients).

The researchers found that HCC that was alcohol-related was more likely to be diffuse and detected in patients with a worse performance status and worse liver function. The median OS was 9.7 and 5.7 months in groups NA and A, respectively (P=0.0002), after adjustments for a lead-time bias; in alcohol-abstinent and alcohol-non-abstinent groups, median OS was 5.8 and 5.0 months, respectively (P=0.09). When survival was assessed at each Barcelona Clinic Liver Cancer (BCLC) stage, the prognostic role of alcohol disappeared. Increased lead time-adjusted median OS was seen for patients with HCC detected during a cirrhosis follow-up program (199 patients) compared to those with HCC diagnosed incidentally (11.7 versus 5.4 months; P<0.0001).

“In comparison with patients with non-alcohol-related HCC, patients with alcohol-related HCC have reduced OS, mainly because of worse liver function and tumor characteristics at diagnosis, as attested by similar survival within each BCLC stage,” the authors write.


Continue Reading

Abstract/Full Text (subscription or payment may be required)